此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

The Aim of the Study is to Characterize Patients Exhibiting Muscular Atrophy and Weakness Who Require a Muscle Biopsy for Diagnosis (IBM vs Atypical MND), Through an Innovative Technique Which Enables the Evaluation of the Neuromuscular Junction Involvement in Each Condition (TDP-signatures)

2026年8月26日 更新者:Stefano Previtali、IRCCS San Raffaele

Comparative Analysis of TDP-43 Pathology in Skeletal Muscle Biopsies With Electrostimulation for Enhanced Neuromuscular Junction Sampling in Patients Affected by Inclusion Body Myopathy (IBM) and Motor Neuron Disease (MND)

The aim of the study is to characterize 30 patients exhibiting muscular atrophy and weakness who require a muscle biopsy for diagnosis (suspected inclusion body myopathy vs atypical motor neuron disease), through an innovative technique (a muscle biopsy with Electrostimulation for Enhanced Neuromuscular Junction sampling), to evaluate the involvement of the neuromuscular junction in each disease and to better characterize shared and divergent patterns of TDP-43 pathology within the peripheral nervous system in both disorders.

研究概览

研究类型

观察性的

注册 (估计的)

30

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Milan、意大利
        • IRCCS Ospedale San Raffaele

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不适用

取样方法

非概率样本

研究人群

30 adult patients with a neuromuscular disorder (suspected IBM or in differential diagnosis between IBM and MND)

描述

Inclusion Criteria:

  • Patients exhibiting progressive muscle weakness and atrophy with a classic clinical IBM pattern or with an atypical clinical IBM pattern or with an atypical MND pattern
  • Able to understand and sign the informed consent
  • Treated according to standard of care clinical practice

Exclusion Criteria:

  • Contraindications to needle EMG or skeletal muscle biopsy
  • Psychiatric diseases that may interfere with adherence to the follow-up protocol

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

队列和干预

团体/队列
运动神经元疾病
Inclusion body myopathy

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Diagnostic sensitivity of an integrated clinical, neurophysiological, metabolic and histopathological model in the differential diagnosis between IBM and MND.
大体时间:At the end of the follow-up period (24 months of follow-up)
To achieve a diagnostic sensitivity of >90% for the differential diagnosis between IBM and MND integrating clinical variables (site of onset, scales reflecting disease progression rate, muscle strength), neurophysiological indices (presence and degree of active denervation signs, presence of myopathic or neurogenic motor unit potentials), histopathological parameters (myopathic or neuropathic pattern of disease) and metabolic measures (hyper- vs hypo-metabolism) into a multivariable binary logistic regression model, using the final diagnosis confirmed during longitudinal follow-up as the reference standard.
At the end of the follow-up period (24 months of follow-up)

次要结果测量

结果测量
措施说明
大体时间
To evaluate signs of muscle and neuromuscular junction (NMJ) involvement at neuropathological level in each disease
大体时间:At the end of the follow-up period (24 months of follow-up)
To investigate disease-specific histological signatures, comparing the pattern of fiber degeneration, the presence of inflammatory infiltrates, the presence of protein aggregation markers (such as pTDP-43) and their localization, the presence of mitochondrial changes (the percentage of age-exceeding number of COX-negative fibers) and the NMJ involvement by evaluating the presynaptic and postsynaptic integrity (quantified as the percentage of synaptophysin and Ach-R clustering, respectively) between IBM and MND (through Fisher's exact test or Mann-Whitney U test, as appropriate) and to evaluate the prognostic role of each histological parameter (through Kaplan-Meier followed by log-rank test and Cox proportional hazards regression).
At the end of the follow-up period (24 months of follow-up)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年7月1日

初级完成 (估计的)

2028年7月1日

研究完成 (估计的)

2030年7月1日

研究注册日期

首次提交

2026年8月20日

首先提交符合 QC 标准的

2026年8月26日

首次发布 (实际的)

2026年9月1日

研究记录更新

最后更新发布 (实际的)

2026年9月1日

上次提交的符合 QC 标准的更新

2026年8月26日

最后验证

2026年8月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅